Abstract
BackgroundDevelopment of disease-modifying drugs for OA has been challenging, partly due to lack of predictive biomarkers.ObjectivesOur primary objective was to identify baseline (BL) biomarkers predicting greater treatment effects on WOMAC...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
